1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs

 
• By Cathy Kelly

Amgen's Prolia appears to be the biggest drug on the list of products incurring price inflation penalties in Part B; many of the others have relatively low sales to Medicare.

Second List Of Drugs Subject To Price Inflation Rebates In Part B Released • Source: Shutterstock

Seven of Amgen, Inc.’s drugs will incur Medicare Part B price inflation rebates in the third quarter, including its blockbuster bone density treatment Prolia, according to a list released by the Centers for Medicare and Medicaid Services on 9 June.

Amgen has more drugs on the list for the period than other manufacturer

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

More from Government Payers

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.